MPM BioVentures 2014, L.P. (EVNIN LUKE, GADICKE ANSBERT) sold $617K of TRDA (indirect holdings)
MPM BioVentures 2014, L.P. sold 86,482 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.14 ($7.06–$7.19, $0.62M total) across 3 trades over 2026-09-01 to 2026-09-03. Filed jointly with EVNIN LUKE (10% owner), GADICKE ANSBERT (10% owner), Foley Todd (10% owner), MPM BioVentures 2014 (B), L.P. (10% owner), MPM Asset Management Investors BV2014 LLC (10% owner), MPM BioVentures 2014 LLC (10% owner), MPM BioVentures 2014 GP LLC (10% owner), MPM BIOVENTURES 2018 (B), L.P. (10% owner) and MPM ASSET MANAGEMENT INVESTORS BV2018 LLC (10% owner).
How this was made
The 30-second read
Why it matters
For TRDA, the actionable takeaway is sentiment and positioning risk from a large-holder reducing exposure. However, absent any accompanying corporate event, the impact is typically modest.
Market read
A 10% owner group sold about $617k of TRDA shares across three trades at roughly $7.14 weighted average, with no 10b5-1 plan cited.
What to watch
The filing does not state a 10b5-1 plan, but it also provides no reason for the sale; without follow-on buying or accompanying corporate news, traders may overreact.
Background
The article is an SEC Form 4 insider transaction disclosure for Entrada Therapeutics, Inc. (TRDA), showing open-market sales by an affiliate/10% owner group.
Ticker impact
MPM BioVentures 2014, L.P., a 10% owner, sold 86,482 TRDA shares in open-market trades at about $7.06 to $7.19 (Form 4).
Likely limited, short-lived sentiment impact; any price effect should be small versus broader fundamentals.
The filing is a Form 4 open-market sale with no 10b5-1 plan stated, but it is not accompanied by new company fundamentals, guidance, or a transaction like a buyout or financing.
Market effects
Minimal, as this is company-specific insider selling with no sector-wide regulatory or clinical catalyst.
None indicated.
None indicated.
Counterpoint
Large-owner sales can be routine liquidity management or tax-related, especially when spread across multiple days, so the signal may be weaker than it looks.
Key entities
- issuerEntrada Therapeutics, Inc.
TRDA, the company whose shares were sold by a 10% owner group via open-market transactions.
- insider_entityMPM BioVentures 2014, L.P.
Reporter and 10% owner that sold TRDA shares indirectly.
